33 active not recruiting. 33 Phase 2, 4 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 33 | Active not recruiting 33 |
| Phase 1 | 4 | Active not recruiting 4 |
| Phase 3 | 4 | Active not recruiting 4 |
Follow Pneumonia: new trials by email Literature Review of Pneumonia trials Research Report on Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults NDV-HXP-S-KP.2, COVID-19 mRNA Vaccine - COVID-19 | Phase 2 | Active not recruiting | CastleVax Inc. | 200 | 2025-11-03 | 2026-07-22 |
| The Long COVID Treatment Trial Tirzepatide, Placebo - Long COVID | Phase 2 | Active not recruiting | Scripps Translational Science Institute | 1000 | 2025-10-30 | 2025-12-23 |
| A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD Verekitug, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Active not recruiting | Upstream Bio Inc. | 666 | 2025-07-02 | 2026-07-20 |
| A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women GBS-NN/NN2 vaccine - Streptococcus Agalactiae Infection, Neonatal Sepsis | Phase 2 / Phase 3 | Active not recruiting | Minervax ApS | 137 | 2025-03-07 | 2026-09-04 |
| Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID Abrocitinib, Placebo - Post-COVID Condition, Fatigue Symptom | Phase 2 | Active not recruiting | Beth Israel Deaconess Medical Center | 46 | 2024-12-27 | 2026-04-20 |
| A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31 - Pneumococcal Vaccines | Phase 2 | Active not recruiting | Vaxcyte, Inc. | 900 | 2024-11-25 | 2026-05-15 |
| A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3 - SARS-CoV2, COVID-19 | Phase 2 | Active not recruiting | Vaxart | 5485 | 2024-10-08 | 2026-10-09 |
| Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID Ensitrelvir, Placebo - Long COVID, Post Acute Sequelae of COVID-19 | Phase 2 | Active not recruiting | Timothy Henrich | 40 | 2024-04-09 | 2026-04-02 |
| Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction Sodium Citrate, Normal Saline, Olfactory Training Kit - "The Olfactory Kit, by AdvancedRx" - Long Haul COVID-19, Post-Acute COVID-19 Syndrome | Phase 2 | Active not recruiting | University of North Carolina, Chapel Hill | 60 | 2023-12-01 | 2025-02-20 |
| Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19) AER002, Placebo - Long COVID, Post-Acute Sequela of COVID-19 | Phase 2 | Active not recruiting | Michael Peluso, MD | 36 | 2023-08-01 | 2025-10-28 |
| Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia CAL02, Placebo - Pneumonia, Bacterial | Phase 2 | Active not recruiting | Eagle Pharmaceuticals, Inc. | 276 | 2023-07-22 | 2026-01-28 |
| A Nasal Treatment for COVID-19 Optate, Placebo - COVID-19, Healthy | Phase 2 | Active not recruiting | Indiana University | 24 | 2023-06-27 | 2026-05-28 |
| Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome Vericiguat Oral Tablet - Post-COVID ME/CFS | Phase 2 | Active not recruiting | Charite University, Berlin, Germany | 104 | 2023-06-22 | 2026-01-28 |
| Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET) Citicoline, Saline/Placebo - COVID-19 | Phase 1 / Phase 2 | Active not recruiting | Ohio State University | 80 | 2023-06-06 | 2025-04-02 |
| A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia Azeliragon, Placebo - COVID-19 | Phase 2 / Phase 3 | Active not recruiting | The University of Texas Medical Branch, Galveston | 144 | 2023-05-04 | 2025-03-03 |
| Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial CI-581a, CI-581b - Post-acute Sequelae of COVID-19, Depressive Symptoms | Phase 2 | Active not recruiting | New York State Psychiatric Institute | 12 | 2023-03-20 | 2024-07-16 |
| Improving Mental Health Among the LGBTQ+ Community Acceptance-Based Behavior Therapy (ABBT), Treatment-as-Usual (TAU) - Anxiety, Depression | Phase 2 | Active not recruiting | Brown University | 240 | 2023-01-25 | 2026-10-13 |
| Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia. AV-001 Injection, AV-001 Placebo Injection - Acute Respiratory Distress Syndrome, Viral or Bacterial Infections | Phase 2 | Active not recruiting | Vasomune Therapeutics, Inc. | 60 | 2021-12-20 | 2026-09-29 |
| SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1 - COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm | Phase 2 | Active not recruiting | GeoVax, Inc. | 63 | 2021-09-27 | 2026-02-11 |
| Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis Sirolimus - Pulmonary Fibrosis, COVID-19 Pneumonia | Phase 2 / Phase 3 | Active not recruiting | University of Chicago | 60 | 2021-07-09 | 2025-12-15 |
Showing 20 of 33. Sign in to see all of them.
COVID-19 (21) · Post-Acute COVID-19 Syndrome (8) · Respiratory Distress Syndrome (4) · Bacterial Infections (2) · Depression (2) · Acute Kidney Injury (1) · Anosmia (1) · Anxiety Disorders (1) · Bacterial Infections and Mycoses (1) · Bronchitis, Chronic (1) · Cognitive Dysfunction (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Disease (1)
Lung Diseases (33) · Respiratory Tract Diseases (33) · Infections (32) · Respiratory Tract Infections (32) · Coronaviridae Infections (27) · Coronavirus Infections (27) · Nidovirales Infections (27) · Pneumonia, Viral (27) · RNA Virus Infections (27) · Virus Diseases (27) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Chronic Disease (9) · Disease Attributes (9)
Saline Solution (3) · BNT162 Vaccine (2) · Sodium Chloride (2) · 2019-nCoV Vaccine mRNA-1273 (1) · Acetylcysteine (1) · Appointments and Schedules (1) · COH04S1 COVID-19 vaccine (1) · COVID-19 Vaccines (1) · CVnCoV COVID-19 vaccine (1) · Celecoxib (1) · ChAdOx1 nCoV-19 (1) · Cyclosporine (1) · Cyproheptadine (1) · Cytidine Diphosphate Choline (1) · Dexamethasone (1)
Ohio State University (2) · Belfast Health and Social Care Trust (1) · Beth Israel Deaconess Medical Center (1) · Brown University (1) · Canadian Immunization Research Network (1) · CastleVax Inc. (1) · Centre Hospitalier Universitaire, Amiens (1) · Charite University, Berlin, Germany (1) · Eagle Pharmaceuticals, Inc. (1) · Ever Supreme Bio Technology Co., Ltd. (1) · GeoVax, Inc. (1) · Indiana University (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Mayo Clinic (1)
United States (27) · Argentina (3) · Canada (3) · United Kingdom (3) · Brazil (2) · Chile (2) · Colombia (2) · Czechia (2) · France (2) · Georgia (2) · Germany (2) · Hungary (2) · Latvia (2) · Romania (2) · Serbia (2)
Amanda Olson (1) · Arnab Chakravarti, MD (1) · Ayodeji Adegunsoye, MD, MS (1) · Brent A. Senior, MD, FACS, FARS (1) · Brian Ward, MD (1) · Danny F McAuley, Professor (1) · David H Ingbar, MD (1) · Denise L Faustman, MD, PhD (1) · Derek W Russell, MD (1) · Elias Dakwar, MD (1) · Ethan Moitra, Ph.D. (1) · James Cummings, MD (1) · Jean-Philippe Lanoix, MD (1) · Joanne Langley (1)
PMID 32493473, PMID 33127750, PMID 34473343, PMID 34746723, PMID 34992881, PMID 35507508, PMID 35562778, PMID 36027906, PMID 36883141, PMID 37146874, PMID 37154608, PMID 38760804, PMID 39536121, PMID 39592213, PMID 40462830, PMID 42799508
2025 (1), P30CA033572 (1), R01AG064802 (1), RF1MH132348 (1)